v3.26.1
Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2026
Jun. 27, 2024
Feb. 28, 2026
Jun. 30, 2025
Oct. 31, 2023
Jun. 30, 2026
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Oct. 14, 2025
Jun. 27, 2025
Mar. 20, 2025
Nov. 30, 2024
Nov. 16, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Revenues             $ 1,110,956 $ 393,572              
Restricted cash and cash equivalents $ 908,459           908,459                
Deferred Tax Asset, In-Process Research and Development 1,062,083           1,062,083                
Milestone payment       $ 250,000                      
Payments for royalties     $ 200,000                        
Gates Foundation [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Accounts receivable                           $ 3,092,136  
Proceeds from grant 2,353,393                            
Revenues             252,969                
Cost of revenue             230,620                
Grant receivable                             $ 3,092,000
Gates Foundation [Member] | Subsequent Event [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Proceeds from grant           $ 738,743                  
Fondazione Biotecnopolo Di Siena Fbs [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Accounts receivable 695,075           695,075                
Grant receivable                         $ 4,500,000    
Grant receivable                         $ 2,432,756    
CEPI [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Revenues             234,398                
Cost of revenue             220,987                
Proliant Agreement [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Cost of revenue             253,000                
License and development initial term   10 years                          
License and development extension term   3 years                          
Initial up front payment                       $ 500,000      
Second payment upon completion transfer                       $ 500,000      
Final payment upon meeting certain productivity threshold                     $ 500,000        
[custom:ResearchAndDevelopmentRevenue-0]                 $ 227,000            
Research and development revenue                 142,300            
Deferred revenue $ 273,000           $ 273,000   273,000            
Inzymes Agreement Aps [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Non refundable upfront payment received         $ 600,000                    
Deferred license revenue                 $ 25,000            
Inzymes Agreement Aps [Member] | Research and Development Arrangement [Member]                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Deferred license revenue                   $ 890,169